Breast Breaking News

podcasts

15/05/2024

05:00

36:21

Impacto do Estrogênio Isolado no Risco de Câncer de Mama: Insights de Ensaios Clínicos e PHERGain Trial: Avanços Promissores no Tratamento do Câncer de Mama HER2-Positiv

Breast Breaking News

Podcast

Mastologia

Português

09/05/2024

05:00

22:10

Concordância do HER2: Biópsia vs. Ressecção Cirúrgica no Câncer de Mama

Breast Breaking News

Podcast

Mastologia

02/05/2024

05:00

12:02

Impacto da resposta à ressonância magnética na previsão da Resposta Tumoral Axilar pós QTNeoadjuv. em pacientes com axila cN1-3

Breast Breaking News

Podcast

Mastologia

Português

25/04/2024

05:00

33:45

Estudo Inovador: Radioterapia Pré-Mastectomia e Reconstrução Imediata da Mama / Quimioterapia Beneficia Pacientes com Câncer de Mama Triplo-Negativo T1b/c.

Breast Breaking News

Podcast

Mastologia

Português

Artigos

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3

Artigo

Breast Breaking News

Mastologia

08/05/2024

Inglês

Survival After Contralateral Axillary Metastasis in Breast Cancer

Artigo

Breast Breaking News

Mastologia

11/04/2024

Inglês

Randomized trials of estrogen‑alone and breast cancer incidence: a meta‑analysis

Artigo

Breast Breaking News

Mastologia

19/02/2024

Inglês

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 tria

Artigo

Breast Breaking News

Mastologia

03/04/2024

Inglês

Breast Breaking News

podcasts

Artigos

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3

Survival After Contralateral Axillary Metastasis in Breast Cancer

Randomized trials of estrogen‑alone and breast cancer incidence: a meta‑analysis

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 tria

Receba nossa
Programação Semanal

Precisa de ajuda?

Nos chame no chat da página!

Breast Breaking News

podcasts

Artigos

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3

Survival After Contralateral Axillary Metastasis in Breast Cancer

Randomized trials of estrogen‑alone and breast cancer incidence: a meta‑analysis

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 tria

Receba nossa Programação Semanal

Precisa de ajuda?

Nos chame no chat da página!

Receba nossa
Programação Semanal